Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today ...
Zacks.com on MSN21h
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study DataAs the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...
Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to ...
Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...
On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax ...
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback